JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Boston Scientific Corp.

Uždarymo kaina

SektoriusSveikatos priežiūra

101.13 -1.24

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

101.02

Max

101.42

Pagrindiniai rodikliai

By Trading Economics

Pajamos

123M

795M

Pardavimai

398M

5.1B

P/E

Sektoriaus vid.

59.135

37.461

Pelno marža

15.708

Darbuotojai

53,000

EBITDA

155M

1.4B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+25.06% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-4.6B

149B

Ankstesnė atidarymo kaina

102.37

Ankstesnė uždarymo kaina

101.13

Naujienos nuotaikos

By Acuity

30%

70%

68 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Boston Scientific Corp. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-22 11:00; UTC

Uždarbis

Boston Scientific Raises Outlook on Continued Cardiovascular Growth

2025-10-17 11:43; UTC

Įsigijimai, susijungimai, perėmimai

Boston Scientific to Buy Rest of Nalu Medical for $533 Million

2025-07-23 11:16; UTC

Uždarbis

Boston Sci 2Q Net Surges, Company Boosts '25 EPS View on Cardiology Demand

2025-10-22 10:32; UTC

Uždarbis

Boston Scientific Sees 4Q Organic Sales Up 11%-13% >BSX

2025-10-22 10:32; UTC

Uždarbis

Boston Scientific Sees 4Q Sales Up 14.5-16.5% >BSX

2025-10-22 10:31; UTC

Uždarbis

Boston Scientific Sees 2025 Organic Sales Up About 15.5% >BSX

2025-10-22 10:31; UTC

Uždarbis

Boston Scientific Sees 2025 Sales Up About 20% >BSX

2025-10-22 10:30; UTC

Uždarbis

Boston Scientific Sees FY Adj EPS $3.02-Adj EPS $3.04 >BSX

2025-10-22 10:30; UTC

Uždarbis

Boston Scientific 3Q Organic Sales Up 15.3% >BSX

2025-10-22 10:30; UTC

Uždarbis

Boston Scientific 3Q Adj EPS 75c >BSX

2025-10-22 10:30; UTC

Uždarbis

Boston Scientific Sees FY EPS $1.97-EPS $2.01 >BSX

2025-10-22 10:30; UTC

Uždarbis

Boston Scientific Sees 4Q EPS 48c-EPS 52c >BSX

2025-10-22 10:30; UTC

Uždarbis

Boston Scientific 3Q Sales $5.07B >BSX

2025-10-22 10:30; UTC

Uždarbis

Boston Scientific 3Q EPS 51c >BSX

2025-10-22 10:30; UTC

Uždarbis

Boston Scientific Sees 4Q Adj EPS 77c-Adj EPS 79c >BSX

2025-10-17 11:02; UTC

Įsigijimai, susijungimai, perėmimai

Boston Scientific to Make Upfront Cash Payment of About $533 Million for Nalu Equity it Doesn't Already Own >BSX

2025-10-17 11:02; UTC

Įsigijimai, susijungimai, perėmimai

Boston Scientific: Nalu Acquisition to Expand Neuromodulation Offerings for People Living With Chronic Pain >BSX

2025-10-17 11:01; UTC

Įsigijimai, susijungimai, perėmimai

Boston Scientific: Nalu Medical Focused on Developing Minimally Invasive Solutions for Chronic Pain >BSX

2025-10-17 11:00; UTC

Įsigijimai, susijungimai, perėmimai

Boston Scientific Announces Agreement To Acquire Nalu Medical, Inc. >BSX

2025-09-09 12:58; UTC

Įsigijimai, susijungimai, perėmimai

Boston Scientific to Buy Elutia's Bioenvelope Business for $88M

2025-09-09 12:31; UTC

Įsigijimai, susijungimai, perėmimai

Elutia Announces Sale of BioEnvelope Business to Boston Scientific for $88M

2025-07-23 10:32; UTC

Uždarbis

Boston Scientific Sees 3Q Sales Up 17%-19%, Organic Sales Up 12%-14% >BSX

2025-07-23 10:31; UTC

Uždarbis

Boston Scientific Sees 2025 Sales Up 18%-19%, Organic Sales Up 14%-15% >BSX

2025-07-23 10:30; UTC

Uždarbis

Boston Scientific Sees FY EPS $1.89-EPS $1.93 >BSX

2025-07-23 10:30; UTC

Uždarbis

Boston Scientific 2Q Organic Sales Up 17.4% >BSX

2025-07-23 10:30; UTC

Uždarbis

Boston Scientific 2Q EPS 53c >BSX

2025-07-23 10:30; UTC

Uždarbis

Boston Scientific 2Q Sales $5.06B >BSX

2025-07-23 10:30; UTC

Uždarbis

Boston Scientific Sees 3Q Adj EPS 70c-Adj EPS 72c >BSX

2025-07-23 10:30; UTC

Uždarbis

Boston Scientific 2Q Adj EPS 75c >BSX

2025-07-23 10:30; UTC

Uždarbis

Boston Scientific Sees FY Adj EPS $2.95-Adj EPS $2.99 >BSX

Akcijų palyginimas

Kainos pokytis

Boston Scientific Corp. Prognozė

Kainos tikslas

By TipRanks

25.06% į viršų

12 mėnesių prognozė

Vidutinis 126.45 USD  25.06%

Aukščiausias 140 USD

Žemiausias 113 USD

Remiantis 24 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Boston Scientific Corp. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

24 ratings

23

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

102.95 / 104.93Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Weak Bearish Evidence

Ilgalaikis periodas

No Evidence

Rinkos nuotaikos

By Acuity

68 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat